| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 49 | 2021 | 1085 | 6.430 |
Why?
|
| Hypoglycemic Agents | 29 | 2021 | 362 | 4.330 |
Why?
|
| Metformin | 19 | 2022 | 63 | 4.050 |
Why?
|
| Cardiovascular Diseases | 19 | 2021 | 940 | 2.870 |
Why?
|
| Blood Glucose | 22 | 2020 | 631 | 2.820 |
Why?
|
| Metabolic Syndrome | 12 | 2019 | 191 | 2.650 |
Why?
|
| Spinal Fractures | 4 | 2021 | 43 | 2.230 |
Why?
|
| Glucocorticoids | 3 | 2021 | 222 | 1.970 |
Why?
|
| Diabetes Mellitus | 11 | 2022 | 694 | 1.800 |
Why?
|
| Veterans | 18 | 2022 | 904 | 1.610 |
Why?
|
| Life Style | 14 | 2021 | 338 | 1.580 |
Why?
|
| Osteoporotic Fractures | 3 | 2020 | 9 | 1.560 |
Why?
|
| Risk Reduction Behavior | 6 | 2018 | 174 | 1.470 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 143 | 1.460 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 154 | 1.450 |
Why?
|
| Drug Discovery | 2 | 2020 | 94 | 1.350 |
Why?
|
| Humans | 118 | 2023 | 68618 | 1.280 |
Why?
|
| Antiviral Agents | 2 | 2020 | 211 | 1.240 |
Why?
|
| Aged | 62 | 2022 | 14862 | 1.200 |
Why?
|
| Obesity | 10 | 2017 | 1076 | 1.180 |
Why?
|
| Fibrous Dysplasia of Bone | 2 | 2017 | 6 | 1.180 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 203 | 1.140 |
Why?
|
| Risk Factors | 32 | 2021 | 5731 | 1.120 |
Why?
|
| Dry Eye Syndromes | 7 | 2014 | 12 | 1.120 |
Why?
|
| Middle Aged | 66 | 2022 | 21147 | 1.090 |
Why?
|
| Bone Density Conservation Agents | 4 | 2019 | 43 | 1.060 |
Why?
|
| Osteoporosis | 3 | 2022 | 88 | 1.040 |
Why?
|
| Male | 79 | 2022 | 37321 | 1.030 |
Why?
|
| Female | 76 | 2022 | 38074 | 0.990 |
Why?
|
| Betacoronavirus | 3 | 2020 | 116 | 0.980 |
Why?
|
| Veterans Health | 5 | 2019 | 62 | 0.970 |
Why?
|
| Pandemics | 4 | 2020 | 352 | 0.970 |
Why?
|
| Quality of Life | 9 | 2019 | 1515 | 0.960 |
Why?
|
| Bone Density | 5 | 2021 | 159 | 0.950 |
Why?
|
| Insulin | 10 | 2022 | 619 | 0.930 |
Why?
|
| Cross-Sectional Studies | 20 | 2021 | 2279 | 0.920 |
Why?
|
| Molecular Docking Simulation | 2 | 2020 | 78 | 0.880 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2023 | 8 | 0.870 |
Why?
|
| Cholesterol | 3 | 2022 | 331 | 0.870 |
Why?
|
| Insulin Resistance | 6 | 2021 | 241 | 0.860 |
Why?
|
| Glucose Intolerance | 2 | 2020 | 36 | 0.820 |
Why?
|
| Anticholesteremic Agents | 1 | 2022 | 49 | 0.820 |
Why?
|
| Hypercholesterolemia | 1 | 2022 | 86 | 0.810 |
Why?
|
| Genome-Wide Association Study | 4 | 2021 | 240 | 0.800 |
Why?
|
| Exercise | 8 | 2020 | 658 | 0.790 |
Why?
|
| Weight Loss | 6 | 2020 | 319 | 0.790 |
Why?
|
| Adult | 39 | 2023 | 21403 | 0.770 |
Why?
|
| Coronary Artery Disease | 4 | 2019 | 696 | 0.750 |
Why?
|
| Cancellous Bone | 1 | 2020 | 2 | 0.730 |
Why?
|
| Lumbar Vertebrae | 2 | 2021 | 112 | 0.720 |
Why?
|
| Vitamin D | 6 | 2014 | 516 | 0.710 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2021 | 157 | 0.700 |
Why?
|
| Femur | 1 | 2020 | 113 | 0.690 |
Why?
|
| Diabetes Complications | 5 | 2020 | 249 | 0.680 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 179 | 0.680 |
Why?
|
| Diphosphonates | 2 | 2016 | 39 | 0.680 |
Why?
|
| Denosumab | 1 | 2019 | 2 | 0.660 |
Why?
|
| Diabetic Nephropathies | 2 | 2019 | 161 | 0.660 |
Why?
|
| Computational Biology | 1 | 2020 | 190 | 0.660 |
Why?
|
| Ichthyosis | 1 | 2018 | 3 | 0.650 |
Why?
|
| Acantholysis | 1 | 2018 | 4 | 0.650 |
Why?
|
| Porokeratosis | 1 | 2018 | 4 | 0.650 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 378 | 0.630 |
Why?
|
| Diabetic Neuropathies | 2 | 2017 | 33 | 0.610 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2017 | 3 | 0.600 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 51 | 0.590 |
Why?
|
| Etanercept | 1 | 2017 | 12 | 0.590 |
Why?
|
| Software | 1 | 2020 | 418 | 0.590 |
Why?
|
| Body Weight | 5 | 2020 | 554 | 0.580 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 59 | 0.580 |
Why?
|
| Rituximab | 1 | 2017 | 61 | 0.570 |
Why?
|
| Methylprednisolone | 1 | 2017 | 99 | 0.560 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 2016 | 3 | 0.560 |
Why?
|
| United States | 28 | 2022 | 7367 | 0.540 |
Why?
|
| Aged, 80 and over | 19 | 2020 | 4848 | 0.540 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 166 | 0.540 |
Why?
|
| Family Health | 2 | 2011 | 83 | 0.540 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 110 | 0.540 |
Why?
|
| Triglycerides | 3 | 2017 | 184 | 0.540 |
Why?
|
| Feeding and Eating Disorders | 1 | 2017 | 106 | 0.530 |
Why?
|
| Prediabetic State | 5 | 2019 | 48 | 0.520 |
Why?
|
| Aging | 4 | 2018 | 911 | 0.500 |
Why?
|
| Mental Disorders | 4 | 2021 | 659 | 0.500 |
Why?
|
| Risk Assessment | 8 | 2020 | 2007 | 0.480 |
Why?
|
| Diet, Mediterranean | 1 | 2014 | 12 | 0.470 |
Why?
|
| Patient Education as Topic | 5 | 2017 | 425 | 0.470 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2021 | 786 | 0.450 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 319 | 0.440 |
Why?
|
| Biomarkers | 6 | 2021 | 1593 | 0.440 |
Why?
|
| Prevalence | 12 | 2019 | 1619 | 0.430 |
Why?
|
| Physical Fitness | 2 | 2019 | 117 | 0.430 |
Why?
|
| Comparative Effectiveness Research | 3 | 2020 | 36 | 0.420 |
Why?
|
| Cognition | 5 | 2021 | 513 | 0.420 |
Why?
|
| Self Care | 2 | 2014 | 253 | 0.410 |
Why?
|
| Young Adult | 15 | 2020 | 5717 | 0.410 |
Why?
|
| Coronary Disease | 2 | 2011 | 358 | 0.410 |
Why?
|
| Motor Activity | 2 | 2015 | 621 | 0.400 |
Why?
|
| Adult Children | 1 | 2011 | 7 | 0.390 |
Why?
|
| Primary Prevention | 1 | 2012 | 115 | 0.390 |
Why?
|
| Hyperglycemia | 4 | 2019 | 158 | 0.380 |
Why?
|
| Sex Factors | 7 | 2020 | 1266 | 0.380 |
Why?
|
| Longevity | 1 | 2011 | 60 | 0.380 |
Why?
|
| Medication Adherence | 2 | 2014 | 335 | 0.370 |
Why?
|
| Hyperlipidemias | 2 | 2005 | 90 | 0.370 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 161 | 0.360 |
Why?
|
| Absorptiometry, Photon | 2 | 2020 | 83 | 0.360 |
Why?
|
| Frailty | 2 | 2021 | 34 | 0.350 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 581 | 0.340 |
Why?
|
| Surveys and Questionnaires | 13 | 2019 | 2800 | 0.340 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2019 | 11 | 0.340 |
Why?
|
| Glucagon-Like Peptides | 2 | 2019 | 15 | 0.340 |
Why?
|
| Venezuela | 5 | 2020 | 6 | 0.340 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 107 | 0.330 |
Why?
|
| Insulin Glargine | 2 | 2019 | 6 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 931 | 0.330 |
Why?
|
| Depressive Disorder | 5 | 2014 | 621 | 0.330 |
Why?
|
| Incidence | 8 | 2019 | 1603 | 0.320 |
Why?
|
| Parents | 1 | 2011 | 312 | 0.310 |
Why?
|
| Diet | 3 | 2018 | 514 | 0.310 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 3259 | 0.310 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2018 | 7 | 0.310 |
Why?
|
| Nutrition Disorders | 2 | 2007 | 16 | 0.310 |
Why?
|
| Mobility Limitation | 1 | 2008 | 27 | 0.310 |
Why?
|
| Hypertriglyceridemia | 2 | 2005 | 21 | 0.310 |
Why?
|
| Age Factors | 6 | 2019 | 1864 | 0.310 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 376 | 0.300 |
Why?
|
| Hyperinsulinism | 2 | 1999 | 23 | 0.300 |
Why?
|
| Treatment Outcome | 12 | 2019 | 7029 | 0.300 |
Why?
|
| Health Status | 2 | 2019 | 429 | 0.290 |
Why?
|
| Health Care Costs | 1 | 2010 | 346 | 0.290 |
Why?
|
| Vitamin D Deficiency | 4 | 2011 | 292 | 0.290 |
Why?
|
| Bulimia Nervosa | 1 | 2006 | 21 | 0.280 |
Why?
|
| Cohort Studies | 8 | 2021 | 2358 | 0.270 |
Why?
|
| Fractures, Bone | 2 | 2022 | 132 | 0.270 |
Why?
|
| Apolipoprotein C-III | 1 | 2005 | 12 | 0.270 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 180 | 0.270 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 565 | 0.260 |
Why?
|
| Body Mass Index | 5 | 2017 | 867 | 0.260 |
Why?
|
| Global Health | 2 | 2016 | 136 | 0.260 |
Why?
|
| Sulfonylurea Compounds | 3 | 2020 | 17 | 0.260 |
Why?
|
| Patient Selection | 1 | 2019 | 592 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 627 | 0.260 |
Why?
|
| Diabetes, Gestational | 2 | 2015 | 81 | 0.250 |
Why?
|
| Telemedicine | 2 | 2010 | 700 | 0.250 |
Why?
|
| Health Transition | 1 | 2014 | 3 | 0.240 |
Why?
|
| Thiazolidinediones | 3 | 2015 | 77 | 0.240 |
Why?
|
| Bone Remodeling | 2 | 2021 | 45 | 0.230 |
Why?
|
| Feeding Behavior | 2 | 2017 | 224 | 0.230 |
Why?
|
| Hypoglycemia | 3 | 2019 | 72 | 0.230 |
Why?
|
| Comorbidity | 7 | 2016 | 1426 | 0.220 |
Why?
|
| Lipoproteins, LDL | 1 | 2005 | 343 | 0.220 |
Why?
|
| Tears | 2 | 2013 | 9 | 0.220 |
Why?
|
| Sitagliptin Phosphate | 2 | 2020 | 4 | 0.220 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 792 | 0.220 |
Why?
|
| Health Behavior | 2 | 2016 | 458 | 0.210 |
Why?
|
| Cognition Disorders | 2 | 2020 | 342 | 0.210 |
Why?
|
| Liraglutide | 2 | 2020 | 18 | 0.210 |
Why?
|
| Independent Living | 2 | 2020 | 44 | 0.210 |
Why?
|
| Fractures, Stress | 1 | 2022 | 12 | 0.200 |
Why?
|
| Health Status Indicators | 3 | 2014 | 117 | 0.200 |
Why?
|
| Osteocalcin | 1 | 2021 | 37 | 0.200 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 805 | 0.200 |
Why?
|
| Dyslipidemias | 2 | 2017 | 98 | 0.200 |
Why?
|
| Confidence Intervals | 3 | 2011 | 242 | 0.200 |
Why?
|
| Inflammation | 1 | 2008 | 1030 | 0.200 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 37 | 0.190 |
Why?
|
| Alkaline Phosphatase | 1 | 2021 | 71 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2011 | 880 | 0.190 |
Why?
|
| Program Evaluation | 3 | 2013 | 502 | 0.190 |
Why?
|
| Dietary Supplements | 3 | 2014 | 332 | 0.190 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2021 | 20 | 0.190 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 137 | 0.190 |
Why?
|
| Bone and Bones | 1 | 2021 | 145 | 0.190 |
Why?
|
| Metabolic Diseases | 1 | 2021 | 37 | 0.190 |
Why?
|
| Collagen Type I | 1 | 2021 | 175 | 0.180 |
Why?
|
| Hypogonadism | 1 | 2020 | 9 | 0.180 |
Why?
|
| Potassium | 2 | 2018 | 168 | 0.180 |
Why?
|
| Economic Recession | 1 | 2020 | 8 | 0.180 |
Why?
|
| Transients and Migrants | 1 | 2020 | 22 | 0.180 |
Why?
|
| Sacroiliac Joint | 1 | 2020 | 3 | 0.180 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Rheumatic Diseases | 1 | 2020 | 35 | 0.180 |
Why?
|
| Ankylosis | 1 | 2020 | 5 | 0.180 |
Why?
|
| China | 1 | 2020 | 138 | 0.180 |
Why?
|
| Fasting | 3 | 2018 | 75 | 0.180 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 1054 | 0.180 |
Why?
|
| Cytosine | 1 | 2019 | 12 | 0.170 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 45 | 0.170 |
Why?
|
| Gene-Environment Interaction | 1 | 2019 | 31 | 0.170 |
Why?
|
| Support Vector Machine | 1 | 2019 | 15 | 0.170 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2019 | 22 | 0.170 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2014 | 1506 | 0.170 |
Why?
|
| Alcoholism | 1 | 2018 | 1109 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2019 | 307 | 0.170 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2020 | 139 | 0.170 |
Why?
|
| Osteitis Deformans | 1 | 2019 | 19 | 0.170 |
Why?
|
| Myocardial Infarction | 3 | 2019 | 807 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 186 | 0.160 |
Why?
|
| Time Factors | 7 | 2018 | 4655 | 0.160 |
Why?
|
| Preventive Health Services | 1 | 2019 | 86 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2022 | 326 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 186 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 35 | 0.160 |
Why?
|
| Adenoma | 1 | 2020 | 132 | 0.160 |
Why?
|
| Blood Pressure | 4 | 2021 | 1451 | 0.160 |
Why?
|
| Logistic Models | 3 | 2013 | 1420 | 0.160 |
Why?
|
| Protective Factors | 2 | 2018 | 24 | 0.160 |
Why?
|
| Mental Health Services | 1 | 2020 | 199 | 0.160 |
Why?
|
| Osteomalacia | 1 | 2017 | 8 | 0.150 |
Why?
|
| Alendronate | 1 | 2017 | 4 | 0.150 |
Why?
|
| Urban Population | 2 | 2017 | 255 | 0.150 |
Why?
|
| Depression | 2 | 2020 | 943 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 199 | 0.150 |
Why?
|
| Phosphorus | 1 | 2017 | 64 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 170 | 0.150 |
Why?
|
| Chondrocalcinosis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Bone Cysts | 1 | 2017 | 5 | 0.150 |
Why?
|
| Hemochromatosis | 1 | 2017 | 13 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2018 | 3705 | 0.150 |
Why?
|
| Age Distribution | 4 | 2017 | 320 | 0.150 |
Why?
|
| Sodium | 1 | 2018 | 161 | 0.150 |
Why?
|
| Social Class | 1 | 2017 | 127 | 0.150 |
Why?
|
| Talus | 1 | 2017 | 18 | 0.150 |
Why?
|
| Internet | 1 | 2020 | 390 | 0.150 |
Why?
|
| Models, Theoretical | 1 | 2020 | 384 | 0.140 |
Why?
|
| Overweight | 2 | 2016 | 186 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2017 | 311 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2021 | 439 | 0.140 |
Why?
|
| Leisure Activities | 1 | 2016 | 22 | 0.140 |
Why?
|
| Health Records, Personal | 1 | 2016 | 8 | 0.140 |
Why?
|
| Glycemic Index | 1 | 2017 | 28 | 0.140 |
Why?
|
| Aftercare | 1 | 2017 | 114 | 0.140 |
Why?
|
| Sex Distribution | 3 | 2019 | 274 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 99 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2016 | 21 | 0.140 |
Why?
|
| Reference Values | 1 | 2017 | 579 | 0.140 |
Why?
|
| Endocrinology | 1 | 2016 | 16 | 0.140 |
Why?
|
| Pilot Projects | 5 | 2017 | 1342 | 0.140 |
Why?
|
| Algorithms | 2 | 2019 | 1196 | 0.140 |
Why?
|
| Hypertension | 3 | 2021 | 1535 | 0.130 |
Why?
|
| Glucose Tolerance Test | 3 | 2012 | 75 | 0.130 |
Why?
|
| Public Health | 1 | 2018 | 201 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2016 | 53 | 0.130 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 30 | 0.130 |
Why?
|
| Economics, Medical | 1 | 2015 | 8 | 0.130 |
Why?
|
| Receptors, Glucagon | 1 | 2015 | 6 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2017 | 252 | 0.130 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 20 | 0.130 |
Why?
|
| Liver | 1 | 2021 | 1118 | 0.130 |
Why?
|
| Linear Models | 3 | 2013 | 521 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2017 | 267 | 0.120 |
Why?
|
| Risk | 4 | 2015 | 563 | 0.120 |
Why?
|
| Sarcopenia | 1 | 2014 | 9 | 0.120 |
Why?
|
| Polypharmacy | 1 | 2014 | 31 | 0.120 |
Why?
|
| Health Promotion | 2 | 2017 | 407 | 0.120 |
Why?
|
| Nutrition Surveys | 4 | 2019 | 208 | 0.120 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2014 | 12 | 0.120 |
Why?
|
| Marijuana Smoking | 1 | 2015 | 108 | 0.120 |
Why?
|
| Nutrition Assessment | 1 | 2014 | 43 | 0.120 |
Why?
|
| Air Pollutants, Occupational | 1 | 2014 | 7 | 0.120 |
Why?
|
| Frail Elderly | 2 | 2020 | 31 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 951 | 0.120 |
Why?
|
| Mass Screening | 2 | 2017 | 843 | 0.120 |
Why?
|
| Adolescent | 4 | 2020 | 8912 | 0.120 |
Why?
|
| Health Literacy | 1 | 2014 | 63 | 0.120 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 41 | 0.120 |
Why?
|
| Hospitalization | 1 | 2020 | 978 | 0.120 |
Why?
|
| Dyspnea | 1 | 2014 | 87 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2014 | 289 | 0.110 |
Why?
|
| Spain | 2 | 2007 | 34 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2013 | 32 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.110 |
Why?
|
| Afghan Campaign 2001- | 1 | 2014 | 78 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2017 | 413 | 0.110 |
Why?
|
| Diet, Reducing | 1 | 2013 | 46 | 0.110 |
Why?
|
| Anthropometry | 2 | 2007 | 64 | 0.110 |
Why?
|
| Remission Induction | 1 | 2013 | 111 | 0.110 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2014 | 85 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 649 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 504 | 0.110 |
Why?
|
| Sickness Impact Profile | 1 | 2013 | 27 | 0.110 |
Why?
|
| Meibomian Glands | 1 | 2013 | 4 | 0.110 |
Why?
|
| Conjunctiva | 1 | 2013 | 16 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2016 | 374 | 0.110 |
Why?
|
| Cornea | 1 | 2013 | 76 | 0.110 |
Why?
|
| Lipids | 2 | 2021 | 298 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 767 | 0.100 |
Why?
|
| Phacoemulsification | 1 | 2013 | 69 | 0.100 |
Why?
|
| Accidental Falls | 2 | 2010 | 84 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1553 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2019 | 62 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 772 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 438 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2014 | 269 | 0.100 |
Why?
|
| Social Support | 1 | 2014 | 423 | 0.100 |
Why?
|
| Cataract | 1 | 2013 | 134 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2019 | 1738 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2324 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1046 | 0.090 |
Why?
|
| C-Peptide | 1 | 2020 | 23 | 0.090 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2020 | 17 | 0.090 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 1242 | 0.090 |
Why?
|
| Databases, Factual | 2 | 2012 | 622 | 0.090 |
Why?
|
| Disease Progression | 1 | 2014 | 1038 | 0.090 |
Why?
|
| Medicare Part C | 1 | 2010 | 2 | 0.090 |
Why?
|
| Preferred Provider Organizations | 1 | 2010 | 2 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 22 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2020 | 24 | 0.090 |
Why?
|
| Muscle Relaxants, Central | 1 | 2010 | 13 | 0.090 |
Why?
|
| Florida | 2 | 2011 | 221 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 163 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 103 | 0.090 |
Why?
|
| Vitamins | 1 | 2011 | 134 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 1465 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2011 | 122 | 0.090 |
Why?
|
| Europe | 1 | 2020 | 196 | 0.090 |
Why?
|
| Cholecalciferol | 1 | 2011 | 143 | 0.090 |
Why?
|
| Workload | 1 | 2011 | 103 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.080 |
Why?
|
| Albuminuria | 2 | 2020 | 171 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2018 | 402 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 274 | 0.080 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 45 | 0.080 |
Why?
|
| Trust | 1 | 2019 | 75 | 0.080 |
Why?
|
| Propensity Score | 2 | 2022 | 117 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 1745 | 0.080 |
Why?
|
| Migraine Disorders | 1 | 2019 | 66 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 420 | 0.080 |
Why?
|
| Interviews as Topic | 1 | 2019 | 392 | 0.080 |
Why?
|
| Muscle Fatigue | 1 | 2008 | 16 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 2018 | 18 | 0.080 |
Why?
|
| Self Medication | 1 | 2007 | 25 | 0.080 |
Why?
|
| Phenotype | 1 | 2021 | 947 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2019 | 369 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2007 | 53 | 0.070 |
Why?
|
| Complementary Therapies | 1 | 2007 | 43 | 0.070 |
Why?
|
| Muscle Weakness | 1 | 2007 | 26 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2008 | 75 | 0.070 |
Why?
|
| Radiography | 2 | 2020 | 572 | 0.070 |
Why?
|
| Psychometrics | 1 | 2010 | 514 | 0.070 |
Why?
|
| Health Surveys | 2 | 2014 | 489 | 0.070 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 307 | 0.070 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2007 | 86 | 0.070 |
Why?
|
| Self Report | 1 | 2018 | 371 | 0.070 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2005 | 48 | 0.060 |
Why?
|
| Indians, South American | 1 | 2005 | 12 | 0.060 |
Why?
|
| Particle Size | 1 | 2005 | 201 | 0.060 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.060 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2014 | 28 | 0.060 |
Why?
|
| Infant | 1 | 2020 | 2891 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2020 | 3187 | 0.060 |
Why?
|
| Homeostasis | 1 | 2005 | 291 | 0.060 |
Why?
|
| Exercise Therapy | 2 | 2019 | 183 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.060 |
Why?
|
| Pregnancy | 2 | 2015 | 2334 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 468 | 0.060 |
Why?
|
| Prognosis | 1 | 2018 | 2093 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2014 | 206 | 0.050 |
Why?
|
| Sternum | 1 | 2022 | 19 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2021 | 52 | 0.050 |
Why?
|
| Smoking | 1 | 2019 | 1452 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2021 | 72 | 0.050 |
Why?
|
| Chest Pain | 1 | 2022 | 151 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2009 | 737 | 0.050 |
Why?
|
| Colombia | 1 | 2020 | 8 | 0.050 |
Why?
|
| Unemployment | 1 | 2020 | 18 | 0.050 |
Why?
|
| Albumins | 1 | 2020 | 72 | 0.050 |
Why?
|
| Ossification of Posterior Longitudinal Ligament | 1 | 2020 | 1 | 0.050 |
Why?
|
| Longitudinal Ligaments | 1 | 2020 | 3 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 41 | 0.040 |
Why?
|
| Calibration | 1 | 2020 | 73 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 127 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2021 | 159 | 0.040 |
Why?
|
| Animals | 1 | 2017 | 20881 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 282 | 0.040 |
Why?
|
| Metabolome | 1 | 2019 | 15 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 125 | 0.040 |
Why?
|
| Child | 1 | 2020 | 6405 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 1999 | 20 | 0.040 |
Why?
|
| Income | 1 | 2020 | 167 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 1999 | 112 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 98 | 0.040 |
Why?
|
| Age of Onset | 1 | 1999 | 188 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 1999 | 87 | 0.040 |
Why?
|
| Creatinine | 1 | 2019 | 243 | 0.040 |
Why?
|
| Calcinosis | 1 | 2020 | 241 | 0.040 |
Why?
|
| West Indies | 1 | 2018 | 5 | 0.040 |
Why?
|
| South America | 1 | 2018 | 8 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 38 | 0.040 |
Why?
|
| New York City | 1 | 2017 | 49 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 2017 | 31 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2017 | 8 | 0.040 |
Why?
|
| Ecuador | 1 | 2017 | 8 | 0.040 |
Why?
|
| Phlebotomy | 1 | 2017 | 17 | 0.040 |
Why?
|
| Postprandial Period | 1 | 2017 | 21 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 536 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 107 | 0.040 |
Why?
|
| Sagittal Abdominal Diameter | 1 | 2016 | 1 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 1667 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 2017 | 73 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 42 | 0.030 |
Why?
|
| Poverty | 1 | 2017 | 219 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 61 | 0.030 |
Why?
|
| Pedigree | 1 | 1995 | 159 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2017 | 340 | 0.030 |
Why?
|
| Television | 1 | 2015 | 28 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 780 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 248 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 195 | 0.030 |
Why?
|
| Thyroid Diseases | 1 | 2011 | 33 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2011 | 40 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2011 | 107 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 216 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Workplace | 1 | 2011 | 75 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 117 | 0.020 |
Why?
|
| Occupational Health | 1 | 2010 | 41 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 955 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2010 | 112 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 411 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 148 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2010 | 130 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 240 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 306 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2009 | 49 | 0.020 |
Why?
|
| Common Cold | 1 | 2007 | 8 | 0.020 |
Why?
|
| Back Pain | 1 | 2007 | 30 | 0.020 |
Why?
|
| Brain | 2 | 2009 | 2176 | 0.020 |
Why?
|
| Tai Ji | 1 | 2007 | 1 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2009 | 206 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1040 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 255 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2007 | 239 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 929 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 91 | 0.020 |
Why?
|
| Stroke | 1 | 2019 | 2163 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2008 | 396 | 0.020 |
Why?
|
| Walking | 1 | 2007 | 241 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 824 | 0.010 |
Why?
|